Patient-specific B-cell lymphoma immunoglobulin idiotype (Id)

The patient-specific B-cell lymphoma immunoglobulin idiotype is a unique tumor-specific antigen (TSA) formed by the variable regions of the monoclonal immunoglobulin (Ig) expressed on the surface of malignant B-cells. Since B-cell lymphomas arise from the clonal expansion of a single transformed B-cell, the resulting idiotype is unique to that patient's tumor and is not expressed by healthy B-lymphocytes or other tissues (Bendandi, M., 2009, Expert Rev Vaccines). This high degree of specificity makes the idiotype an ideal target for personalized active immunotherapy, primarily through the development of idiotype vaccines. These vaccines are designed to induce a host immune response, including both cytotoxic T-lymphocytes and anti-idiotype antibodies, specifically directed against the malignant clone (Inoges, S., et al., 2006, Journal of the National Cancer Institute). While clinical trials for candidates like Dasiprotimut-T have demonstrated the ability to prolong disease-free survival in specific patient subsets, the approach faces significant hurdles including the necessity for bespoke manufacturing for every patient and the potential for tumor escape via antigen downregulation.

Other names

Tumor-specific idiotypeB-cell receptor idiotypeBCR idiotypeId antigenClonal immunoglobulin variable region

Active immunotherapy involving the administration of a patient-specific idiotype protein, typically conjugated to a carrier protein like Keyhole Limpet Hemocyanin (KLH) and administered with an adjuvant (e.g., GM-CSF), to stimulate a personalized T-cell and B-cell mediated anti-tumor immune response against the unique variable regions of the malignant B-cell receptor (Levy, R., 2010, PubMed; Schuster, S. J., et al., 2011, JCO).